INBX - Inhibrx, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
La Jolla,
United States
Type: Equity
INBX price evolution
INBX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $277.92 | $337.33 | $192.49 | $234.25 |
| Short term investments | ||||
| Net receivables | $0.78 | $0.33 | $0.33 | $0.3 |
| Inventory | ||||
| Total current assets | $295.36 | $363.3 | $203.32 | $243.78 |
| Long term investments | ||||
| Property, plant & equipment | $9.37 | $6.27 | $6.68 | $6.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.54 | $9.44 | $9.85 | $9.94 |
| Total investments | ||||
| Total assets | $307.89 | $372.73 | $213.17 | $253.72 |
| Current liabilities | ||||
| Accounts payable | $10.95 | $7.86 | $9.7 | $10.92 |
| Deferred revenue | $0.12 | $0.15 | ||
| Short long term debt | $2.06 | $2.01 | $1.96 | $1.91 |
| Total current liabilities | $56.31 | $35.77 | $31.33 | $32.64 |
| Long term debt | $208.08 | $207.37 | $206.65 | $205.94 |
| Total noncurrent liabilities | $208.08 | $207.37 | $206.65 | $205.94 |
| Total debt | $210.14 | $209.38 | $208.61 | $207.85 |
| Total liabilities | $264.39 | $243.14 | $237.98 | $238.58 |
| Shareholders' equity | ||||
| Retained earnings | -$613.73 | -$520.13 | -$468.34 | -$421.29 |
| Other shareholder equity | ||||
| Total shareholder equity | $43.5 | $129.59 | -$24.81 | $15.13 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $277.92 | $273.87 | $131.3 | $128.66 |
| Short term investments | ||||
| Net receivables | $0.78 | $0.26 | $0.88 | $0.61 |
| Inventory | ||||
| Total current assets | $295.36 | $280.49 | $139.11 | $132.17 |
| Long term investments | ||||
| Property, plant & equipment | $9.37 | $7.22 | $9.49 | $11.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.54 | $10.38 | $11.34 | $11.57 |
| Total investments | ||||
| Total assets | $307.89 | $290.88 | $150.45 | $143.74 |
| Current liabilities | ||||
| Accounts payable | $10.95 | $8.33 | $9.13 | $13.46 |
| Deferred revenue | $0.17 | $2.14 | $3.82 | |
| Short long term debt | $2.06 | $1.86 | $1.67 | $1.5 |
| Total current liabilities | $56.31 | $27.58 | $22.45 | $31.4 |
| Long term debt | $208.08 | $202.07 | $75.5 | $35.95 |
| Total noncurrent liabilities | $208.08 | $205.24 | $75.61 | $36.87 |
| Total debt | $210.14 | $207.1 | $77.18 | $37.45 |
| Total liabilities | $264.39 | $232.82 | $98.07 | $68.27 |
| Shareholders' equity | ||||
| Retained earnings | -$613.73 | -$372.37 | -$227.15 | -$145.38 |
| Other shareholder equity | ||||
| Total shareholder equity | $43.5 | $58.06 | $52.38 | $75.47 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.63 | $0.12 | $0.03 | $0.02 |
| Cost of revenue | ||||
| Gross Profit | $1.63 | $0.12 | $0.03 | $0.02 |
| Operating activities | ||||
| Research & development | $82.09 | $38.06 | $34.11 | $37.39 |
| Selling, general & administrative | $7.83 | $7.89 | $7.26 | $6.4 |
| Total operating expenses | $89.92 | $45.95 | $41.37 | $43.78 |
| Operating income | -$88.29 | -$45.83 | -$41.34 | -$43.77 |
| Income from continuing operations | ||||
| EBIT | -$85.39 | -$43.64 | -$39.14 | -$43.84 |
| Income tax expense | -$0 | $0 | $0.01 | |
| Interest expense | $8.22 | $8.15 | $7.91 | $5.08 |
| Net income | ||||
| Net income | -$93.6 | -$51.79 | -$47.05 | -$48.92 |
| Income (for common shares) | -$93.6 | -$51.79 | -$47.05 | -$48.92 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.8 | $2.19 | $7.23 | $12.89 |
| Cost of revenue | ||||
| Gross Profit | $1.8 | $2.19 | $7.23 | $12.89 |
| Operating activities | ||||
| Research & development | $191.64 | $110.19 | $71.44 | $73.5 |
| Selling, general & administrative | $29.38 | $21.12 | $12.36 | $6.84 |
| Total operating expenses | $221.02 | $131.31 | $83.8 | $80.33 |
| Operating income | -$219.22 | -$129.12 | -$76.56 | -$67.44 |
| Income from continuing operations | ||||
| EBIT | -$209.52 | -$129.12 | -$76.55 | -$65.31 |
| Income tax expense | $0 | $0 | $0 | $0 |
| Interest expense | $31.84 | $16.11 | $5.22 | $10.82 |
| Net income | ||||
| Net income | -$241.36 | -$145.23 | -$81.77 | -$76.12 |
| Income (for common shares) | -$241.36 | -$145.23 | -$81.77 | -$76.12 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$93.6 | -$51.79 | -$47.05 | -$48.92 |
| Operating activities | ||||
| Depreciation | $0.75 | $0.75 | $0.73 | $0.72 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.43 | $6.53 | $6.25 | $5.64 |
| Total cash flows from operations | -$56.82 | -$54.24 | -$42.3 | -$39.94 |
| Investing activities | ||||
| Capital expenditures | -$3.44 | -$0.81 | -$0.32 | -$0.02 |
| Investments | ||||
| Total cash flows from investing | -$3.44 | -$0.81 | -$0.32 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.86 | $199.89 | $0.85 | $0.36 |
| Net borrowings | ||||
| Total cash flows from financing | $0.86 | $199.89 | $0.85 | $0.36 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$59.4 | $144.84 | -$41.76 | -$39.61 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$241.36 | -$145.23 | -$81.77 | -$76.12 |
| Operating activities | ||||
| Depreciation | $2.96 | $2.85 | $2.69 | $2.39 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $24.85 | $20.45 | $15.05 | $5.02 |
| Total cash flows from operations | -$193.31 | -$115.3 | -$80.32 | -$47.97 |
| Investing activities | ||||
| Capital expenditures | -$4.59 | -$0.69 | -$0.81 | -$1.36 |
| Investments | ||||
| Total cash flows from investing | -$4.59 | -$0.69 | -$0.81 | -$1.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $201.96 | $130.13 | $44.16 | $136.88 |
| Net borrowings | $128.81 | $39.99 | $40.57 | |
| Total cash flows from financing | $201.96 | $258.55 | $83.77 | $166.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.06 | $142.56 | $2.64 | $117.12 |
News
Fundamentals
| Market cap | $1.63B |
|---|---|
| Enterprise value | $1.56B |
| Shares outstanding | 47.37M |
| Revenue | $1.80M |
|---|---|
| EBITDA | -$209.04M |
| EBIT | -$212.00M |
| Net Income | -$241.36M |
| Revenue Q/Q | 496.35% |
| Revenue Y/Y | -17.88% |
| P/E ratio | -6.75 |
|---|---|
| EV/Sales | 867.10 |
| EV/EBITDA | -7.47 |
| EV/EBIT | -7.36 |
| P/S ratio | 904.76 |
| P/B ratio | 37.44 |
| Book/Share | 0.92 |
| Cash/Share | 5.87 |
| EPS | -$5.10 |
|---|---|
| ROA | -84.13% |
| ROE | -590.78% |
| Debt/Equity | 6.08 |
|---|---|
| Net debt/EBITDA | 0.06 |
| Current ratio | 5.25 |
| Quick ratio | 5.25 |